Doctors are exploring a potential treatment for glioblastoma, a deadly brain cancer, using a drug derived from olive oil. The early trial results show promise in treating this aggressive tumor, which typically has a bleak prognosis.
Glioblastoma affects thousands of Americans each year, with a survival time averaging just eight months. The experimental drug, called idroxioleic acid or 2-OHOA, alters the walls of tumor cells to impede their growth and spread.
Dr. Michele Afif, CEO of the Brain Tumour Charity, underscores the importance of this research in advancing treatments for glioblastoma patients. Phase 3 clinical trials are eagerly awaited, given the limited progress in treating this challenging disease.
Initial trial results published in the British Journal of Cancer indicate that about 25% of participants responded positively to the oral medication, with one patient surviving over three years. Common side effects included nausea, vomiting, and diarrhea.
Following these encouraging findings, a Phase 3 trial is underway, with a UK cancer research center recruiting over 200 patients.
One participant, Michele Treen, diagnosed with glioblastoma in 2023, shared her positive experience with 2-OHOA. Despite her diagnosis, she remains well and has been able to enjoy activities like traveling across Europe with her family, creating cherished memories along the way.
This development offers hope for patients facing this devastating diagnosis and represents a significant step forward in glioblastoma treatment. However, further research is needed to fully understand the drug’s effectiveness and potential side effects. Nonetheless, the progress made so far is promising, offering a glimmer of hope for those affected by this aggressive form of brain cancer.
